Jessica Baker Flechtner, PhD, chief scientific officer, Genocea, discussed the company’s focus on solid tumors and manufacturing cell therapies.
Jessica Baker Flechtner, PhD
Advertisement
Chief Scientific Officer, Genocea
Articles by Jessica Baker Flechtner, PhD
Jessica Baker Flechtner, PhD, chief scientific officer, Genocea, discussed the ATLAS platform and the TiTAN trial.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
Patients Treated With Spur Therapeutics’ Gaucher Disease Gene Therapy FLT201 Maintain Clinical Benefit for Up to 2 Years
2
Patients Treated With AskBio’s Limb-Girdle Muscular Dystrophy Gene Therapy AB-1003 Free of Serious Adverse Events at Up to 52 Weeks
3
CGTLive®’s Weekly Rewind – October 17, 2025
4
